Evidence map›Paper›PMID 30429313›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Site occupancy calibration of taxane pharmacology in live cells and tissues.

Javier J Pineda, Miles A Miller, Yuyu Song, Hallie Kuhn, Hannes Mikula, Naren Tallapragada, Ralph Weissleder, Timothy J Mitchison

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Pacific Blue-Taxoids as Fluorescent Molecular Probes of Microtubules.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Javier J PinedaDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115; javierjpineda13@gmail.com timothy_mitchison@hms.harvard.edu.
Miles A MillerCenter for Systems Biology, Massachusetts General Hospital, Boston, MA 02114.
Yuyu SongDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115.ORCID 0000-0002-9196-1610
Hallie KuhnDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115.
Hannes MikulaCenter for Systems Biology, Massachusetts General Hospital, Boston, MA 02114.
Naren TallapragadaDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital, Boston, MA 02114.ORCID 0000-0003-0828-4143
Timothy J MitchisonDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115; javierjpineda13@gmail.com timothy_mitchison@hms.harvard.edu.
Harvard University · USMassachusetts General Hospital · US

Funding

MICROTUBULE DYNAMICS AND MITOTIC MECHANISMR01GM039565 · NIGMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI MITCHISON, TIMOTHY J · 1988 to 2018
$6.2M
MICROTUBULE DYNAMICS AND MITOTIC MECHANISMR37GM039565 · NIGMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI MITCHISON, TIMOTHY J · 1997 to 2006
$3.2M
Imaging of nanotherapeutic drug actionU01CA206997 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$2.9M
Single Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast CancerR00CA207744 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, MILES A · 2018 to 2020
$747k
Single Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast CancerK99CA207744 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, MILES A · 2016 to 2017
$359k
Using Quantitative Proteomics to Elucidate the Signaling Consequences of Microtubule DisruptionF31GM117882 · NIGMS · HARVARD MEDICAL SCHOOL · PI PINEDA, JAVIER JESUS · 2016 to 2018
$97k
NCI NIH HHS K99 CA207744NCI NIH HHS R00 CA207744NCI NIH HHS U01 CA206997NIGMS NIH HHS F31 GM117882NIGMS NIH HHS R01 GM039565NIGMS NIH HHS R37 GM039565
6 · The paper itself

Abstract

Drug receptor site occupancy is a central pharmacology parameter that quantitatively relates the biochemistry of drug binding to the biology of drug action. Taxanes and epothilones bind to overlapping sites in microtubules (MTs) and stabilize them. They are used to treat cancer and are under investigation for neurodegeneration. In cells, they cause concentration-dependent inhibition of MT dynamics and perturbation of mitosis, but the degree of site occupancy required to trigger different effects has not been measured. We report a live cell assay for taxane-site occupancy, and relationships between site occupancy and biological effects across four drugs and two cell lines. By normalizing to site occupancy, we were able to quantitatively compare drug activities and cell sensitivities independent of differences in drug affinity and uptake/efflux kinetics. Across all drugs and cells tested, we found that inhibition of MT dynamics, postmitotic micronucleation, and mitotic arrest required successively higher site occupancy. We also found interesting differences between cells and drugs, for example, insensitivity of the spindle assembly checkpoint to site occupancy. By extending our assay to a mouse xenograft tumor model, we estimated the initial site occupancy required for paclitaxel to completely prevent tumor growth as 80%. The most important cellular action of taxanes for cancer treatment may be formation of micronuclei, which occurs over a broad range of site occupancies.

Indexed as

Antineoplastic AgentsBiological TransportBridged-Ring CompoundsCell Line, TumorEpothilonesHumansKineticsMicroscopyMicrotubulesTaxoidsAntineoplastic AgentsBridged-Ring CompoundsEpothilonestaxaneTaxoidsdrug efficacyepothilonemicronucleimicrotubulestaxane

Identifiers

PMID30429313
PMCPMC6275538
OpenAlexW2900958188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.